Inotersen (Transthyretin-Specific Antisense Oligonucleotide) for Treatment of Transthyretin Amyloidosis

References

• Andrade C . A peculiar form of peripheral neuropathy. Familial atypical generalized amyloidosis with special involvement of the peripheral nerves . Brain75, 408 – 427 ( 1952 ).
   PubMed Web of Science ®Google Scholar
• Benson MD , UemichiT . Transthyretin amyloidosis . Amyloid Int. J. Exp. Clin. Invest.3, 44 – 56 ( 1996 ).
   Web of Science ®Google Scholar
• Connors TH , ThebergeR, SkareJet al. A new transthyretin variant (Ser23Asn) associated with familial amyloidosis in a Portuguese patient . Amyloid Int. J. Exp. Clin. Invest.6, 114 – 118 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Robbins J . Thyroxine-binding proteins . Prog. Clin. Biol. Res.5, 331 – 355 ( 1976 ).
   PubMedGoogle Scholar
• Benson MD , Kluve-BeckermanB, LiepnieksJJet al. Metabolism of amyloid proteins . In : The Nature and Origin of Amyloid Fibrils . John Wiley & Sons (Ed.). Ciba Foundation, West Sussex, England, UK ( 1996 ).
   Google Scholar
• Episkopou V , MaedaS, NishiguchiSet al. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinal and thyroid hormone . Proc. Natl Acad. Sci. USA90, 2375 – 2379 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Hamilton JA , SteinraufLK, BradenBCet al. The x-ray crystal structure refinements of normal human transthyretin and the amyloidgenic Val30Met variant to a 1.7-Å resolution . J. Biol. Chem.268, 2416 – 2424 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Benson MD . Other systemic forms of amyloidosis . In : Amyloidosis: Diagnosis and Treatment . GertzMA, RajkumarSJ ( Eds ). Humana Press, New York, NY, USA ( 2010 ).
   Google Scholar
• Nichols WC , DwuletFE, LiepnieksJet al. Variant apolipoprotein AI as a major constituent of a human hereditary amyloid . Biochem. Biophys. Res. Commun.156, 762 – 768 ( 1988 ).
   PubMed Web of Science ®Google Scholar
• Rader DJ , GreggRE, MengMSet al. In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis . J. Lipid Res.33, 755 – 763 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Benson MD , KincaidJC . Invited review - the molecular biology and clinical features of amyloid neuropathy . Muscle Nerve36, 411 – 423 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Koike H , MisuKen-ichiro, IkedaS-i . Type 1 (Transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form . Arch. Neurol.59, 1771 – 1776 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Koike H , MisuM, SuiguraMet al. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy . Neurology63, 129 – 138 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Goren H , SteinbergMC, FarboodyGH . Familial oculoleptomeningeal amyloidosis . Brain103, 473 – 495 ( 1980 ).
   PubMed Web of Science ®Google Scholar
• Petersen RB , GorenH, ChoenMet al. Transthyretin amyloidosis: a new mutation associated with dementia . Ann. Neurol.41, 307 – 313 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Holmgren G , SteenL, EkstedtJet al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidoitic polyneuropathy (FAP-met30) . Clin. Genet.40, 242 – 246 ( 1991 ).
   PubMed Web of Science ®Google Scholar
• Yamashita T , AndoY, OkamotoSet al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy . Neurology78 ( 9 ), 637 – 643 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Liepnieks JJ , BensonMD . Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation . Amyloid14, 277 – 282 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Westermark P , SlettenK, JohanssonB, CornwellGG . Fibril in senile systemic amyloidosis is derived from normal transthyretin . Proc. Natl Acad. Sci. USA87, 2843 – 2845 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Berk JL , SuhrOB, ObiciLet al. Repurposing diflunisal for familial amyloid polyneuropathy: a clinical trial . JAMA310 ( 24 ), 2658 – 2667 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Coehlo T , MaiaLF, Martins da SilvaAet al. Long-term effects of tafamidis for the treatment of transthyretin amyloid polyneuropathy . J. Neurol.260 ( 11 ), 2802 – 2814 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Maurer MS , SchwartzJH, GunadapaneniBet al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy . N. Engl. J. Med.379 ( 11 ), 1007 – 1016 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Adams D , Gonzalez-DuarteA, RiordanWDet al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis . N. Engl. J. Med.379, 11 – 21 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Costa RH . LaiE, DurnellJE . Transcriptional control of the mouse prealbumin (transthyretin) gene: both promoter sequences and a distinct enhancer are cell specific . Mol. Cell Biol.6, 4697 – 4708 ( 1996 ).
   Google Scholar
• Falls HF , JacksonJH, CareyJG, RukavinaJG, BlockWD . Ocular manifestations of hereditary primary systemic amyloidosis . Arch. Ophth.54, 660 – 664 ( 1955 ).
   PubMedGoogle Scholar
• Rukavina JG , BlockWD, JacksonCEet al. Primary systemic amyloidosis: a review and an experimental, genetic and clinical study of 29 cases with particular emphasis on familial form . Medicine35, 239 – 334 ( 1956 ).
   PubMed Web of Science ®Google Scholar
• Dwulet FE , BensonMD . Characterization of a transthyretin (prealbumin) variant associated with familial amyloidotic polyneuropathy Type II (Indiana/Swiss) . J. Clin. Invest.78, 880 – 886 ( 1986 ).
   PubMed Web of Science ®Google Scholar
• Benson MD , Kluve-BeckermanB, ZeldenrustSRet al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides . Muscle Nerve33, 609 – 618 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Benson MD , Waddington-CruzM, BerkJL, PolydefkisMet al. Inotersen treatment for patients with hereditary transthyretin amyloidosis . N. Engl. J. Med.379 ( 1 ), 22 – 31 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Benson MD , DasguptaNR, RissingSM, SmithJessica, FeigenbaumH . Safety and efficacy of a TTR specific oligonucleotide in patients with transthyretin amyloid cardiomyopathy . Amyloid24 ( 4 ), 219 – 225 ( 2017 ).
   PubMed Web of Science ®Google Scholar